#USA #Washington #Nereus #Vanda Pharmaceuticals #Fanapt

Vanda Pharmaceuticals: 2025 Financial and Operational Review

Vanda Pharmaceuticals Inc. recently released its financial results for the fourth quarter and the full year of 2025, highlighting significant growth across its product lines and outlining its future direction in the pharmaceutical industry. With a commitment to developing treatments that address unmet medical needs, Vanda's strategic advancements continue to generate positive momentum.

Financial Overview

In 2025, Vanda recorded a 24% increase in net product sales from its flagship product, Fanapt®, accumulating $117.3 million compared to the previous year. This growth was attributed to a 28% rise in total prescriptions and a remarkable 149% surge in new-to-brand prescriptions, indicating a robust demand for treatments for schizophrenia and bipolar I disorder.

Overall, total revenues surged by 9% to $216.1 million in 2025, up from $198.8 million in 2024. Despite the loss before income taxes expanding to $138.6 million, attributed largely to strategic investments in growth and infrastructure, Vanda remains optimistic about its future trajectory. The company ended the year with $263.8 million in cash and cash equivalents, reflecting its strong financial position.

Key Product Performances

The financial report revealed varying performances among Vanda's key products. Notably, Fanapt® demonstrated substantial growth, contributing significantly to the company's revenue stream. However, HETLIOZ®, another key product, experienced a 7% decline in sales, selling $71.4 million in 2025. PONVORY® sales saw minor fluctuations, ending the year at $27.4 million, a slight decrease from 2024.

With Vanda committed to enhancing the performance of its commercial infrastructure, ongoing investments in marketing and brand visibility are expected to bolster overall sales performance moving into the next year.

Regulatory Milestones

On the regulatory front, Vanda achieved a notable milestone with the FDA approving NEREUS™ (tradipitant) for the prevention of motion-induced vomiting, marking it as a significant advancement in treatment options for this common issue. The drug is expected to have a substantial market impact, targeting around 65-78 million U.S. adults experiencing symptoms of motion sickness.

Meanwhile, the New Drug Application (NDA) for Bysanti™ (milsaperidone), intended for bipolar I disorder and schizophrenia, is currently under FDA review, with a target action date of February 21, 2026. This approval could further expand Vanda's offerings in the psychiatric sector, capitalizing on the approximately $20 billion market.

Future Outlook

Looking ahead, Vanda guided expectations for 2026, projecting total revenues between $230 to $260 million, illustrating its continued optimism for growth driven by Fanapt® and forthcoming product launches. The robust commercial pipeline suggests ongoing opportunities for Vanda to strengthen its market position, particularly within mental health treatments.

Vanda also anticipates launching a comprehensive Phase III study for NEREUS™, targeting its use in patients experiencing vomiting symptoms from GLP-1 analogs. Furthermore, the successful introduction of imsidolimab for generalized pustular psoriasis is also on the horizon, reaffirming Vanda’s commitment to addressing various health conditions.

In summary, Vanda Pharmaceuticals has successfully navigated the complexities of the biopharmaceutical landscape in 2025, showcasing growth in sales, strategic advancements in regulatory approvals, and positioning itself for a stronger market presence in the upcoming years. By continuously investing in building brand awareness and enhancing product offerings, Vanda aims to secure its future and improve the lives of countless patients grappling with significant health challenges.